14th Annual New York & New Jersey Pain Medicine Congress

14th Annual New York & New Jersey Pain Medicine Congress is organized by CongressLine Ltd., New York Society of Interventional Pain Physicians (NYSIPP), New Jersey Society of Interventional Pain Physicians (NJSIPP) and will be held from Nov 06 - 09, 2025 at Hyatt Regency Jersey City on the Hudson, Jersey City, New Jersey, United States of America.

Description:
The NYSIPP & NJSIPP Pain Medicine Symposium was the primary objectives of educating healthcare professionals to promote the development of the safe, high-quality, and cost-effective practice of interventional pain management techniques for the diagnosis and treatment of pain and related disorders and to ensure patient access to these interventions.

Our scientific program will provide cutting-edge information on advanced state-of-the-art pain management techniques, advanced regenerative medicine therapies, advanced neuromodulation therapies and beyond, vertebral augmentation, discography, and intradiscal procedures, radiofrequency, peripheral nerve stimulation, intrathecal therapy, minimally invasive sacroiliac fusion and for lumbar spinal stenosis. This course will offer a full-day hands-on cadaver and ultrasound course, incorporating didactic lectures with hands-on practice for improved technique and patient outcomes for interventional procedures presented by nationally and internationally renowned experts. Additionally, we have focused workshops for residents and fellows, as well as for nurse practitioners and physician assistants.

Industry Partners and technical exhibits are an important part of our meeting’s success and benefit both the attendees and the companies that choose to participate. We anticipate that an excess of 600 clinical providers specializing in pain management, interventional pain management, and neurosurgery will attend, including physicians, mid-level practitioners, fellows, residents, nurses, and pharmacists.

We look forward to seeing you at the 14th Annual of the New York and New Jersey Pain Medicine Congress in November 2025!

Program Needs Assessment:
Interventional Pain management incorporates interventional treatment options for patients to reduce or eliminate the need for chronic conventional medication management (and/or opiate therapy). Interventional treatment options include: spinal cord stimulation, peripheral nerve stimulation, vertebral augmentation, radiofrequency nerve ablation, etc. Since Interventional Pain Management is such a juvenile specialty, very few pain management physicians and anesthesiologists have gone through specific interventional fellowships and residencies. Training in the proper patient selection and utilization of these therapies is limited. Interventionalists need to attend and participate in training programs to receive education and skill-based training in options available for patients.
Additionally, new guidelines are emerging.

It is important for the experts in the field to share the most current information and data available to assist physicians in selecting the right patients and right therapies to improve patient outcomes. Vital topics to be discussed are: New Innovations, Establishing Protocols, Neuromodulation, Complicated Cases, Intrathecal Drug Delivery, Conflicting Evidence and Research. At the conclusion of this meeting, attendees will develop rational guidelines to assist in improving access to care and treatment outcomes for chronic pain patients.

Learning Objectives:

• Evaluate new and established techniques in interventional pain management to optimize treatment for patients with chronic or acute pain syndromes.
• Analyze emerging trends and interpret the latest available data to enhance state-of-the-art medical services.
• Identify educational gaps and integrate updated information to improve patient outcomes.
• Apply evidence-based medicine to support physicians in selecting appropriate patients for therapies.
• Develop a structured format for information sharing and feedback among healthcare professionals.
• Assess the appropriate utilization of screening options and patient selection criteria to identify individuals at significant risk of addiction, misuse, abuse, or diversion of controlled substances prescribed for chronic pain.